NDA 208264 · Adienne SA
Tepadina and Sodium Chloride
Thiotepa · Intravenous, Intracavitary, Intravenous, Intravesical · Alkylating Drug
OrphanLast checked: Nov 19, 2026Latest source record: Jan 15, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Jan 26, 2017
Approved uses
1
Original approval plus efficacy supplements
Registered trials
324
39 Phase 3, 55 recruiting
FAERS reports
9,762
9,540 serious, 2,735 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SEVERE MYELOSUPPRESSION and CARCINOGENICITY TEPADINA may cause severe marrow suppression, and high doses may cause marrow ablation with resulting infection or bleeding. Monitor hematologic laboratory parameters. Hematopoietic progenitor (stem) cell transplantation (HSCT) is required to prevent potentially fatal complications of the prolonged myelosuppression after high doses of TEPADINA [see Warnings and Precautions (5.1) ] TEPADINA should be considered potentially carcinogenic in humans [see Warnings and Precautions (5.7) ] WARNING: SEVERE MYELOSUPPRESSION and CARCINOGENICITY See full prescribing information for complete boxed warning. May cause severe marrow suppression or ablation with resulting infection or bleeding. Monitor hematologic laboratory parameters. (5.1) Potentially carcinogenic in humans. (5.7)
What it is approved for
From the label in effect Jan 30, 2026.
TEPADINA (thiotepa) is an alkylating drug indicated: To reduce the risk of graft rejection when used in conjunction with high-dose busulfan and cyclophosphamide as a preparative regimen for allogeneic hematopoietic progenitor (stem) cell transplantation (HSCT) for pediatric patients with class 3 beta-thalassemia. (1.1 , 14) For treatment of adenocarcinoma of the breast or ovary. (1.2) For controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities. (1.3) For treatment of superficial papillary carcinoma of the urinary bladder. (1.4) 1.1 Class 3 Beta-Thalassemia TEPADINA is indicated to reduce the risk of graft rejection when used in conjunction with high-dose busulfan and cyclophosphamide as a preparative regimen for allogeneic hematopoietic progenitor (stem) cell transplantation (HSCT) for pediatric patients with class 3 beta-thalassemia [see Clinical Studies ( 14 ) ] . 1.2 Adenocarcinoma of the Breast or Ovary TEPADINA is indicated for treatment of adenocarcinoma of the breast or ovary. 1.3 Malignant Effusions TEPADINA is indicated for controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities. 1.4 Superficial Papillary Carcinoma of the Urinary Bladder TEPADINA is indicated for treatment of superficial papillary carcinoma of the urinary bladder. 1.1 Class 3 Beta-Thalassemia TEPADINA is indicated to reduce the risk of graft rejection when used in conjunction with high-dose busulfan and cyclophosphamide as a preparative regimen for allogeneic hematopoietic progenitor (stem) cell transplantation (HSCT) for pediatric patients with class 3 beta-thalassemia [see Clinical Studies ( 14 ) ] . 1.2 Adenocarcinoma of the Breast or Ovary TEPADINA is indicated for...
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 26, 2017 Original approval · Type 5 - New Formulation or New Manufacturer OrphanLabelLetterReview
4 products under this application
- TEPADINA AND SODIUM CHLORIDE · THIOTEPA 200MG · POWDER, INTRAVENOUS · Prescription
- TEPADINA · THIOTEPA 15MG/VIAL · POWDER, INTRACAVITARY, INTRAVENOUS, INTRAVESICAL · Prescription · TE AP
- TEPADINA AND SODIUM CHLORIDE · THIOTEPA 400MG · POWDER, INTRAVENOUS · Prescription
- TEPADINA · THIOTEPA 100MG/VIAL · POWDER, INTRACAVITARY, INTRAVENOUS, INTRAVESICAL · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Thiotepa" as an intervention, any sponsor and status, largest first.
- Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic LeukaemiaPivotal-lookingRecruiting
St. Anna KinderkrebsforschungAcademic, hospital or other
NCT01949129 · 1,800 participants (planned) · Start Apr 2013 · Primary completion Jun 1, 2030
Drug: VP16; Thiotepa and 6 more · For: Acute Lymphoblastic Leukaemia
Sites: Buenos Aires, Argentina; La Plata, Argentina; Melbourne, Australia · 119 sites in all
- High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)Pivotal-lookingRecruiting
Gustave Roussy, Cancer Campus, Grand ParisAcademic, hospital or other
NCT04221035 · 800 participants (planned) · Start Nov 5, 2019 · Primary completion Nov 2026
Drug: Vincristine; Carboplatin and 13 more · For: High-Risk Neuroblastoma; Patient With Insufficient Response Chemoimmunotherapy
Sites: Sydney, Australia; Clayton, Australia; Nedlands, Australia · 142 sites in all
- Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)Pivotal-lookingRecruiting
Children's Oncology GroupResearch network
NCT03126916 · 750 participants (planned) · Start May 14, 2018 · Primary completion Sep 30, 2030
Drug: Busulfan; Carboplatin and 13 more · For: Ganglioneuroblastoma; Ganglioneuroblastoma, Nodular; Neuroblastoma
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 164 sites in all
- Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk NeuroblastomaPivotal-lookingCompleted
Children's Oncology GroupResearch network
NCT00567567 · 665 participants · Start Nov 5, 2007 · Primary completion Feb 27, 2015
Drug: Carboplatin; Cisplatin and 9 more · For: Localized Resectable Neuroblastoma; Localized Unresectable Neuroblastoma; Recurrent Neuroblastoma and 3 more
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 190 sites in all
- S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast CancerPivotal-lookingTerminated
SWOG Cancer Research NetworkResearch network
NCT00002772 · 602 participants · Start Jul 1996 · Primary completion Feb 2004
Drug: filgrastim; carboplatin and 7 more · For: Breast Cancer
Sites: New York, New York
- Standard Chemotherapy Compared With High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Breast CancerPivotal-lookingCompleted
Scottish Cancer Therapy NetworkAcademic, hospital or other
NCT00002755 · 600 participants (planned) · Start Nov 1995
Drug: filgrastim; CMF regimen and 6 more · For: Breast Cancer
Sites: Dublin, Ireland; Cambridge, United Kingdom; Cheltenham, United Kingdom · 21 sites in all
- Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast CancerPivotal-lookingCompleted
Pierre Fabre MedicamentIndustry
NCT01091168 · 594 participants · Start Jul 2009 · Primary completion Aug 27, 2012
Drug: vinflunine; Alkylating agent of physician choice registered in cancer · For: Breast Cancer; Metastases
Sites: Buenos Aires, Argentina; Quilmes, Argentina; Rosario, Argentina · 80 sites in all
Universitätsklinikum Hamburg-EppendorfAcademic, hospital or other
NCT00303810 · 567 participants · Start Jan 2001 · Primary completion Dec 2013
Drug: carboplatin; cisplatin and 7 more · For: Brain and Central Nervous System Tumors
Sites: Hamburg, Germany
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use1,227
- febrile neutropenia853
- mucosal inflammation830
- product use in unapproved indication601
- drug ineffective558
- pyrexia533
- cytomegalovirus infection531
- acute graft versus host disease465
- acute graft versus host disease in skin464
- cytomegalovirus infection reactivation454
- infection435
- neutropenia422
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 49 |
| 2005 | 38 |
| 2006 | 44 |
| 2007 | 36 |
| 2008 | 78 |
| 2009 | 108 |
| 2010 | 159 |
| 2011 | 158 |
| 2012 | 120 |
| 2013 | 88 |
| 2014 | 267 |
| 2015 | 125 |
| 2016 | 221 |
| 2017 | 511 |
| 2018 | 853 |
| 2019 | 853 |
| 2020 | 997 |
| 2021 | 831 |
| 2022 | 672 |
| 2023 | 584 |
| 2024 | 981 |
| 2025 | 1,209 |
| 2026 | 780 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Ferreri AJ, Cwynarski K, Pulczynski E, et al. · Lancet Haematol 2016 · Clinical Trial, Phase II, Multicenter Study
- Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101.
Batchelor TT, Giri S, Ruppert AS, et al. · Blood Adv 2024 · Randomized Controlled Trial, Clinical Trial, Phase II
- Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation?
Sylvester RJ, Oosterlinck W, Holmang S, et al. · Eur Urol 2016 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial.
Ferreri AJM, Cwynarski K, Pulczynski E, et al. · Leukemia 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma.
Wendler J, Fox CP, Valk E, et al. · BMC Cancer 2022 · Clinical Trial, Phase III, Multicenter Study
- Intensive Multimodality Therapy for Extraocular Retinoblastoma: A Children's Oncology Group Trial (ARET0321).
Dunkel IJ, Piao J, Chantada GL, et al. · J Clin Oncol 2022 · Clinical Trial, Research Support, N.I.H., Extramural
Sponsor: Adienne SA · Also marketed as Tepadina
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.